EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant

Opinion
Video

A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content